8-K: Klotho Neurosciences Partners AAVnerGene for Gene Therapy

Klotho Neurosciences, Inc. has entered into a binding agreement with AAVnerGene Inc. to initiate manufacturing and development of its KLTO-202 gene therapy candidate using AAVnerGene's AAVone platform technology.

Summary

• A Binding Letter Agreement was executed between Klotho Neurosciences, Inc. (Klotho) and AAVnerGene Inc. (AAVnerGene) on August 6, 2025.
• The collaboration focuses on AAVnerGene's proprietary AAVone platform technologies for the development of Klotho's gene therapy programs, specifically KLTO-101, KLTO-202, and KLTO-303.
• This Agreement serves as an interim framework to initiate development activities, facilitate payments, and enable the negotiation of a definitive License and Supply Agreement.
• Klotho is required to pay Part I service fees and the full Upfront License Payment associated with KLTO-101 and KLTO-202 within ten (10) business days of the Effective Date.
• AAVnerGene grants Klotho an exclusive option to enter into a License and Supply Agreement covering the AAVnerGene AAVone technology for the development, manufacture, and commercialization of KLTO-101, KLTO-202, and KLTO-303.
• Klotho has fifteen (15) days upon delivery of the KLTO-101 and KLTO-202 constructs to evaluate the materials and decide whether to exercise the License Option.
• A refund provision states that if Klotho does not exercise the License Option, AAVnerGene shall refund 40% of the Upfront License Payment (or 80% if due to failure to meet product specifications).
• The Parties will immediately commence good faith negotiations for a definitive License and Supply Agreement, aiming to finalize it within ninety (90) days of the Effective Date.
• If Klotho exercises its license option, AAVnerGene will complete technology transfer activities and support Klotho's transition to clinical development.
• Upon successful development and regulatory approval, Klotho will pay AAVnerGene royalties on net sales of licensed products, as specified in the Term Sheet.
• Initial fees to be paid by Klotho are $250,000.
• Klotho will pay a two percent (2%) royalty on revenue from all products created using the AAVone platform.

Sentiment

Score: 8

Explanation: The filing announces a strategic partnership that provides Klotho Neurosciences with access to advanced, potentially transformative gene therapy manufacturing and delivery technology. This is expected to accelerate development, reduce costs, and improve safety and efficacy of its product candidates, representing a significant positive development for the company's pipeline and future prospects.

Positives

• Gains access to AAVnerGene's AAVone platform, which is expected to significantly improve gene therapy manufacturing efficiency, reduce impurities, shorten production time, and lower development costs compared to traditional methods.
• Leverages AAVnerGene's ATHENA platform for tissue-specific targeting, which is anticipated to enhance safety and efficacy by reducing liver tropism and inflammatory responses, addressing a major challenge in AAV-vectored gene therapies.
• The partnership has the potential to accelerate the pace of launching product candidates into the clinic, leading to faster development cycles.
• Secures an exclusive option to license the AAVone technology for multiple key gene therapy candidates (KLTO-101, KLTO-202, KLTO-303), providing a strategic advantage for Klotho's pipeline.
• Refund provisions for the upfront payment offer some financial risk mitigation if the license option is not exercised.

Negatives

• Requires significant initial financial commitments, including an upfront payment of $250,000 and ongoing royalties of 2% on net sales.
• The current agreement is an interim framework, necessitating the negotiation and finalization of a definitive License and Supply Agreement, which introduces a degree of uncertainty.
• The refund provisions are partial (40% or 80%), meaning Klotho will still incur some costs even if the license option is not exercised.
• Reliance on a third-party's proprietary technology for core manufacturing and development introduces dependency risks.

Risks

• Inability to implement business plans or identify and realize additional opportunities.
• Failure to meet or exceed financial projections.
• Changes in the regulatory or competitive environment in which the company operates.
• Actual future events could differ materially from forward-looking statements due to various factors.
• The definitive License and Supply Agreement may not be finalized within the 90-day timeframe or on terms favorable to Klotho.
• The AAVone technology may not perform as expected in clinical development, manufacturing scalability, or commercialization.
• Despite claims of mitigation, inherent challenges of AAV-vectored gene therapies, such as potential for inflammatory responses or off-target effects, could still arise.

Future Outlook

Klotho Neurosciences anticipates that leveraging AAVnerGene's AAVone platform will enable a faster pace for launching its product candidates into the clinic, potentially at a lower cost, with higher efficacy, and greater purity compared to current manufacturing methods. The company believes the AAVnerGene technology, particularly the ATHENA system for tissue-specific targeting, will prove highly beneficial and safer by reducing liver tropism and inflammatory responses, thereby improving the overall profile of its gene therapy products.

Management Comments

• "The AAVnerGene technology is a game-changer in manufacturing AAV vectors for intracellular delivery of genes." Dr. Joseph Sinkule, KLOTHO CEO.
• "The initiation of manufacturing is a key milestone in the development of any biotech product, and the manufacturing of gene therapy products presents particular complications." Dr. Joseph Sinkule, KLOTHO CEO.
• "KLOTHO is using AAVnerGene's cutting-edge AAVone platform technology and engineered HEK293 cell line to introduce the plasmid DNA containing our Klotho gene, so that the AAV particles containing our gene are at a higher-than-normal titer concentration, have fewer impurities, and can be optimized and produced faster than the old standard method." Dr. Joseph Sinkule, KLOTHO CEO.
• "We believe that working with AAVnerGene as our development partner has the potential to launch our product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current triple transfection manufacturing method." Dr. Joseph Sinkule, KLOTHO CEO.

Industry Context

The gene therapy industry faces significant hurdles in manufacturing scalability, cost-efficiency, and safety, particularly concerning the production of adeno-associated virus (AAV) vectors and managing off-target effects like liver tropism and inflammatory responses. AAVnerGene's AAVone single-plasmid production system and ATHENA capsid engineering platform directly address these critical bottlenecks by simplifying processes, reducing costs, increasing purity, and enabling precise tissue targeting. This collaboration positions Klotho Neurosciences to leverage these advanced manufacturing and delivery technologies, potentially accelerating its pipeline development in neurodegenerative and age-related disorders and gaining a competitive edge in the rapidly evolving gene therapy landscape.

Comparison to Industry Standards

• AAVnerGene's AAVone system is presented as a significant advancement over the traditional 'triple transfection' method for AAV production, which is described as 'complicated, tedious, labor-intensive process requiring optimization that may take several months or a year to complete.'
• The AAVone system is claimed to 'dramatically increased the production efficiency, simplified the process, reduced the impurity, shortened the time and lowered the development cost' compared to the triple transfection method.
• The ATHENA system for tissue-specific targeting is highlighted as a solution to a major industry challenge, contrasting with 'AAV vectors that traffic to the liver' which are known to 'induce an inflammatory response that causes life-threatening side effects and even death.' This implies a superior safety profile compared to current broad-tropism AAV vectors.

Stakeholder Impact

• **Shareholders**: Potential for increased shareholder value due to accelerated product development, reduced manufacturing costs, and improved efficacy/safety profiles of gene therapy candidates. However, there are upfront financial commitments and ongoing royalty obligations.
• **Employees**: Potential for increased workload and new opportunities related to the collaboration and accelerated clinical development, fostering expertise in cutting-edge gene therapy technologies.
• **Customers (future patients)**: Potential for safer, more effective, and potentially more accessible gene therapies for neurodegenerative and age-related disorders, addressing significant unmet medical needs.
• **Suppliers**: AAVnerGene becomes a critical strategic supplier for Klotho's AAV constructs and related technology.
• **Creditors**: The financial commitments and potential for future revenue streams from successful product commercialization could influence the company's financial stability and creditworthiness.

Next Steps

• AAVnerGene to commence production and delivery of the second-generation AAV construct, AAVone, for KLTO-101 and KLTO-202.
• Parties to jointly prepare and execute a detailed Work Order outlining specific activities.
• Klotho to provide a copy of its Certificate of Analysis (COA).
• Klotho to pay initial service fees and the full Upfront License Payment within ten (10) business days of August 6, 2025.
• Klotho to evaluate delivered materials and notify AAVnerGene of its decision to exercise the License Option within fifteen (15) days of delivery.
• Parties to immediately commence good faith negotiations of a definitive License and Supply Agreement, aiming to finalize it within ninety (90) days of August 6, 2025.
• If Klotho exercises its license option, AAVnerGene will complete all required technology transfer activities and support Klotho's transition to clinical development.
• Upon successful development and regulatory approval, AAVnerGene shall manufacture and supply licensed AAVone-based materials for commercial use, and Klotho (or its partner) shall market and sell finished gene therapy products.

Key Dates

Recommendation

This binding agreement represents a significant strategic advancement for Klotho Neurosciences, securing access to AAVnerGene's innovative AAVone and ATHENA platforms. These technologies promise to dramatically improve the efficiency, cost-effectiveness, purity, and safety of gene therapy manufacturing and delivery, addressing critical industry challenges. The potential for faster clinical development and enhanced product profiles for multiple candidates (KLTO-101, KLTO-202, KLTO-303) positions Klotho for substantial future growth and competitive advantage in the rapidly evolving gene therapy landscape. While there are upfront costs and ongoing royalties, the potential benefits in accelerating the pipeline and improving product quality far outweigh these, making this a highly positive and transformative development for the company.

Keywords

Gene therapy, AAV, AAVone, Klotho Neurosciences, AAVnerGene, Biotechnology, Drug development, Clinical trials, Manufacturing, Licensing agreement, KLTO-202, KLTO-101, KLTO-303, Neurodegenerative disorders, Anti-aging, ALS, Alzheimer's disease, Parkinson's disease, ATHENA platform